Psychiatric adverse events during levetiracetam therapy.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 12963770.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The prevalence and psychopathologic features of psychiatric adverse events (PAE) in 517 patients taking levetiracetam (LEV) were investigated. Fifty-three (10.1%) patients developed PAE. A significant association was found with previous psychiatric history, history of febrile convulsions, and history of status epilepticus, whereas lamotrigine co-therapy had a protective effect. PAE were not related to the titration schedule of LEV, and certain patients seem to be biologically more vulnerable.
Medical subject headings
- Anticonvulsants
- Piracetam
- Psychoses, Substance-Induced